Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tenaya Therapeutics ( (TNYA) ) just unveiled an update.
On March 4, 2026, Tenaya Therapeutics entered into a collaboration agreement with Alnylam Pharmaceuticals to jointly discover and validate up to 15 novel gene targets for potential cardiovascular disease treatments over an initial 24‑month research period. Under the deal, Tenaya will conduct in vitro and in vivo validation work reimbursed by Alnylam within an agreed budget, while Alnylam assumes sole responsibility and cost for subsequent development, manufacturing, regulatory and commercialization activities for any resulting products.
Tenaya granted Alnylam an exclusive worldwide license to use Tenaya’s relevant intellectual property and know‑how for collaboration targets, subject to target‑by‑target continuation based on Alnylam initiating non‑human primate pharmacodynamic studies within a defined evaluation window. In return, Alnylam will pay Tenaya up to $10 million upfront, subject to reductions for certain targets, and Tenaya could receive up to $1.13 billion in development, regulatory and sales‑based milestone payments, positioning the company for significant potential upside while limiting its downstream cost exposure and locking in exclusivity constraints on certain targets during the collaboration term.
The most recent analyst rating on (TNYA) stock is a Sell with a $0.86 price target. To see the full list of analyst forecasts on Tenaya Therapeutics stock, see the TNYA Stock Forecast page.
Spark’s Take on TNYA Stock
According to Spark, TipRanks’ AI Analyst, TNYA is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, sizable losses, and heavy negative free cash flow), implying ongoing dependence on external funding. Technicals remain mixed with a longer-term downtrend and no clear momentum reversal. Corporate events are balanced, with positive regulatory/clinical developments partly offset by elevated Nasdaq listing-compliance risk.
To see Spark’s full report on TNYA stock, click here.
More about Tenaya Therapeutics
Tenaya Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for cardiovascular disease. The company operates in the biopharmaceutical industry, leveraging genetic and molecular approaches to identify novel drug targets and advance treatments for heart-related conditions in global markets.
Average Trading Volume: 5,145,225
Technical Sentiment Signal: Sell
Current Market Cap: $119.1M
For a thorough assessment of TNYA stock, go to TipRanks’ Stock Analysis page.